Kamada Ltd Q2 2026 earnings show 23% revenue growth to $54.9M, with $14.1M in adjusted EBITDA and a strong outlook for continued expansion.
Kamada Ltd reported Q2 2026 revenue of $54.9 million, a 23% increase year-over-year and surpassing the $53 million consensus estimate. The notable growth reflects strong demand for its specialty plasma-derived products and positions the company for continued expansion in the second half of the year.
Key Takeaways
- Total revenues for Q2 2026 reached $54.9 million, up 23% YoY, marking the highest quarterly revenue in the company's history.
- Adjusted EBITDA was $14.1 million, increasing 29% YoY and representing a solid 26% margin of revenues.
- Net income for Q2 was $9.3 million, reflecting a 26% rise YoY.
- Cash flow from operations was approximately $17.8 million for the first half of 2026, compared to $7.5 million in the same period last year.
- 2026 annual revenue guidance remains between $200 million and $205 million, with the company reiterating its objectives after achieving 50% of the midpoint in the first half.
Record Revenues Driven by Product Demand
Kamada Ltd's total revenues for the first six months of 2026 were $100.2 million, a 13% increase compared to $88.8 million for the same period in 2025. The company attributed this growth primarily to higher sales of its leading product, Kedrab, in the U.S. market, along with increased sales of Varizig and Hepagam. For Q2 alone, revenue was the strongest ever recorded, indicating robust demand across Kamada's product lines and effective execution of its growth strategy.
| Metric | Q2 2026 | YoY | QoQ |
|---|---|---|---|
| Revenue | $54.9M | +23% | - |
| Adjusted EBITDA | $14.1M | +29% | - |
| Net Income | $9.3M | +26% | - |
Strategic Growth Pillars Supporting Expansion
The company emphasized that its growth is driven by four strategic pillars: expanding its existing commercial portfolio, enhancing distribution capabilities particularly in the MENA region, ramping up plasma collection in Texas, and pursuing business development and M&A opportunities. The recent signing of a three-year, $50 million plasma supply agreement underscores this strategy and is expected to contribute significantly to future revenues.
Amir London, CEO, noted, > "The underlying demand for our products continues to increase, and we are confident that our growth strategy is working effectively."
Guidance and Outlook: Maintaining Momentum
Kamada reiterated its 2026 guidance of $200 million to $205 million in revenues and $50 million to $53 million in adjusted EBITDA, representing expected growth rates of 12% and 23%, respectively. This guidance reflects the company’s strong first-half performance, with revenues already covering 50% of the midpoint target.
Management indicated that future growth will be further supported by the expansion of its biosimilar products in Israel and ongoing distribution agreements in the MENA region. The company is also optimistic about the upcoming launch of additional biosimilars, projected to generate $15 million to $20 million in annual sales within a few years.
Analyst Q&A: Insight into Financial Performance
During the Q&A session, analysts probed further into the company's financial health and growth prospects. Annabelle Sammy from Sidoti & Company questioned the rationale behind not raising guidance despite strong quarterly results. In response, management emphasized that their current targets remain sufficient given the company’s performance trajectory and ongoing strategies.
Additionally, when asked about the low selling and marketing expenses relative to sales, Amir London explained, > "We have been very effective in the way we are utilizing our resources, ensuring profitable growth while managing expenses efficiently."
Frequently Asked Questions
Did Kamada Ltd beat earnings estimates in Q2 2026?
Yes, Kamada reported earnings per share of $0.23, beating the consensus estimate of $0.21 by 2 cents.
What were Kamada's total revenues for the first half of 2026?
Total revenues for the first half of 2026 were $100.2 million, representing a 13% increase from $88.8 million in the first half of 2025.
What is Kamada's guidance for 2026?
Kamada reiterated its revenue guidance for 2026 to be between $200 million and $205 million, with adjusted EBITDA expected to be between $50 million and $53 million.
How is Kamada's plasma collection strategy progressing?
Kamada's plasma collection strategy is on track, with the company expecting initial plasma sales under a new $50 million contract to commence by year-end 2026.
As Kamada continues to execute its growth strategy while maintaining financial discipline, investors will be closely watching the company’s ability to sustain this momentum through the latter half of the year.
This analysis is based on public earnings call materials and is not investment advice.
